Foghorn Therapeutics

Foghorn Therapeutics is an American biopharmaceutical company that discovers and develops novel drugs to treat cancer and other serious medical disorders. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Foghorn Therapeutics stock price chart
vol.
change
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Foghorn Therapeutics balance sheet

Report period2018 2019 2020 2021 2022 Q3 23
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Foghorn Therapeutics cash flows

Report period2018 2019 2020 2021 2022 Q3 23 TTM
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Foghorn Therapeutics multipliers

Report period2018 2019 2020 2021 2022 Q3 23 TTM
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Foghorn Therapeutics profitability

Report period2018 2019 2020 2021 2022 Q3 23 TTM
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Foghorn Therapeutics assets
Foghorn Therapeutics cash flows

Foghorn Therapeutics dividend policy

The company doesn't provide dividend

Foghorn Therapeutics shares

TickerNameTypeNominal valueISINPrice
FHTX:USFoghorn TherapeuticsCommon share-US3441741077$6.36
General information
Company nameFoghorn Therapeutics
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Pharmaceuticals / Pharmaceuticals
Business address100 Binney Street Suite 610 Cambridge, MA 02142 United States
Mailing address100 Binney Street Suite 610 Cambridge, MA 02142 United States
Websiteir.foghorntx.com
Information disclosurewww.sec.gov